Abbott Laboratories (ABT) is slated to report its third-quarter 2024 results on Oct. 16, before the opening bell. The company delivered adjusted earnings per share (EPS) of $1.14 in the last quarter, which topped the Zacks Consensus Estimate by 3.64%. In the trailing four quarters, its earnings exceeded the Zacks Consensus Estimate on all four occasions, the average beat being 2.34%. Q3 Estimates The Zacks Consensus Estimate for ABT's third-quarter 2024 revenues is pegged at $10.56 billion. This suggests a ...